By univariate analyses, old age (p = 0.015), concomitant HCC (p = 0.023), Child-Pugh A6 (p = 0.002), lower serum albumin level (p < 0.001), higher total bilirubin level (p = 0.004) and lower platelet count (p = 0.015) were associated with the development of hepatic decompensation during PrOD-based therapies. Here, ALB is linked to hepatocellular carcinoma.